Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Launched by MIRAKIND · Sep 26, 2014
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the role of specific genetic changes, called microRNA binding site mutations, in the risk, prevention, and treatment of cancer. Researchers are looking for individuals who may have these mutations, particularly the KRAS-variant, to join their studies. They hope to learn more about how these mutations might affect cancer and related conditions.
To be eligible for this trial, participants should be between 65 and 74 years old and have a personal or family history of cancer, or a personal history of endometriosis or autoimmune diseases. Unfortunately, younger individuals or those who cannot understand English will not be able to participate. Participants will receive their results through a doctor after the study is finished. This research is important as it may lead to better understanding and treatment options for cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Personal or family history of cancer
- • Personal history of endometriosis, or autoimmunity
- Exclusion Criteria:
- • Younger than 18
- • Non-english speaking and unable to understand and sign the consent
About Mirakind
Mirakind is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the field of healthcare. With a commitment to improving patient outcomes, Mirakind collaborates with leading researchers and institutions to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. The organization focuses on developing novel treatments across various therapeutic areas, leveraging cutting-edge technologies and methodologies to ensure the safety and efficacy of its products. Through its strategic partnerships and patient-centric approach, Mirakind aims to transform healthcare delivery and enhance the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Joanne Weidhaas, MDPhD
Principal Investigator
MiraKind
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials